Publications
Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy Vrije Universiteit Brussel KU Leuven
Immune checkpoint blockade combined with IL-6 and TGF-β inhibition improves the therapeutic outcome of mRNA-based immunotherapy Vrije Universiteit Brussel
Improved understanding of cancer immunology has provided insight into the phenomenon of frequent tumor recurrence after initially successful immunotherapy. A delicate balance exists between the capacity of the immune system to control tumor growth and various resistance mechanisms that arise to avoid or even counteract the host's immune system. These resistance mechanisms include but are not limited to (i) adaptive expression of inhibitory ...
Integrating T cell metabolism in cancer immunotherapy Vrije Universiteit Brussel
Activation and maintenance of the T cell response occurs concurrently with metabolic reprogramming. This ensures the T cell response is supported by sufficient energy and substrates necessary for cell survival, growth and proliferation. Different metabolic programs are associated with differentiation into different cell subsets, effector function and development of long-lasting memory. This provides an opportunity to improve the T cell ...
Dendritic cell immunotherapy in uterine cancer Vrije Universiteit Brussel KU Leuven
Modulating co-stimulation during antigen presentation to enhance cancer immunotherapy Vrije Universiteit Brussel
A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Vrije Universiteit Brussel
...
Selective activation of intracellular signalling pathways in dendritic cells for cancer immunotherapy Vrije Universiteit Brussel
Engineering dendritic cells to enhance cancer immunotherapy Vrije Universiteit Brussel
First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes Vrije Universiteit Brussel
BACKGROUND: Type 1 diabetes (T1D) is a CD4+ T cell-driven autoimmune disease characterized by the destruction of insulin-producing pancreatic β-cells by CD8+ T cells. Achieving glycemic targets in T1D remains challenging in clinical practice; new treatments aim to halt autoimmunity and prolong β-cell survival. IMCY-0098 is a peptide derived from human proinsulin that contains a thiol-disulfide oxidoreductase motif at the N-terminus and was ...